Skip to main content

Table 5 Effect of tolvaptan 60 mg at baseline, during, and after systemic inhibition of NO synthesis on brachial systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse rate in a randomized, placebo-controlled, double-blind, crossover study of 18 ADPKD patients

From: Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study

Periods Baseline L-NMMA Post infusion p (GLM-within)
Prior to L-NMMA infusion At the beginning of infusion At the end of infusion 30 min after the end of L-NMMA infusion 60 min after the end of L-NMMA infusion
SBP (mmHG)
 Placebo 137 ± 12 146 ± 17 149 ± 16 147 ± 16 146 ± 13 0.407
 Tolvaptan 60 mg 135 ± 9 144 ± 15 144 ± 14 142 ± 15 144 ± 13
 p (GLM between) 0.305      
 p (paired t-test, between) 0.276 0.623 0.107 0.134 0.332  
DBP (mmHg)
 Placebo 82 ± 10 88 ± 11 90 ± 10 87 ± 9 87 ± 9 0.502
 Tolvaptan 60 mg 81 ± 8 88 ± 9 87 ± 9 85 ± 8 85 ± 8
 p (GLM between) 0.659      
 p (paired t-test, between) 0.410 0.762 0.094 0.101 0.190  
Pulse rate (BPM)
 Placebo 58 ± 9 55 ± 8 55 ± 9 56 ± 9 6 0 ± 10 0.319
 Tolvaptan 60 mg 58 ± 9 54 ± 9 54 ± 9 57 ± 10 60 ± 11
 p (GLM between) 0.991      
 p (paired t-test, between) 0.699 0.431 0.502 0.873 0.966  
  1. Data are given as mean ± SD. General linear model (GLM) with repeated measures was performed for comparison within and between treatment groups. Post-hoc Bonferoni test was used for comparison between L-NMMA infusion period (at the beginning/ at the end of L-NMMA infusion period) vs baseline (prior to L-NMMA infusion period) and baseline vs post infusion period (30 min/60 min after the end of L-NMMA infusion) vs baseline, none of the p- values were significant. Paired t-test was used for comparison between treatment groups